Program Highlights and Speakers

Macfarlane Burnet Speaker: Professor Elizabeth Molyneux

Honorary Professor of Paediatrics and ex head of the Paediatric Department in The College of Medicine and Queen Elizabeth Hospital/College of Medicine in Blantyre, Malawi where she worked for over 30 years. Prof Molyneux's interests are wide and varied and include emergency care, infectious diseases and ‘tropical’ oncology. With WHO she has developed the ETAT (Emergency Triage Assessment and Treatment) course based on the Advanced Paediatric course of the UK (APLS) of which she is a founder member. Infectious diseases and tropical oncology are areas of clinical research and health care delivery in a resource-constrained setting is a major interest. Click here to read about the Macfarlane Burnet Oration.
Read More

International Speaker: Professor John Reeder

Director of TDR, the Special Programme for Research and Training in Tropical Diseases, at the World Health Organization in Geneva, for the last 5 years. He was previously Co-Director of the Centre for Population Health and Head of the Office of International Health Research at the Burnet Institute, Melbourne and an NH&MRC Principal Research Fellow .Prior to this he was Director of the Papua New Guinea Institute of Medical Research, where he worked on translating scientific findings into policy for improved health across research programmes in mosquito-borne diseases, respiratory disease, sexual health, disease surveillance, infectious diseases and therapies, and operational/implementation research. He maintains research interests in malaria and other agents of global health significance, such as tuberculosis, NTDs and HIV. Read More

International Speaker: Professor Pei-Jer Chen

Based at the University of Taiwan, Professor Chen's fields of speciality include Hepatology, Gastroenterology, Internal Medicine, Molecular Virology and Cancer Research. Prof Chen's research interests include animal models of hepatitis B and D infection and replication, Liver tumour related gene mutation, development and clinical trials of novel treatments for hepatitis B and C, new strategies for liver tumour management, including combination therapy, chemo-, immune, and gene therapy. Read More